美国心脏协会卒中委员会发布了关于急性缺血性卒中的现行治疗指南,其中包括应用重组组织型纤溶酶原激活物(rt-PA)行静脉溶栓的建议。尽管该药对改善神经功能预后有一定的疗效,但由于患者通常在发病3 h后方能到达医院,往往已经超过了用药的时间窗。因此,大部分缺血性卒中患者未能接受rt-PA治疗。目前研究认为,增加rt-PA治疗例数的最可能方法就是延长治疗时间窗。欧洲协作急性卒中研究(ECASS)-3是一项前瞻性研究, The American Heart Association Stroke Council publishes current guidelines for treatment of acute ischemic stroke, including recommendations for intravenous thrombolysis using recombinant tissue-type plasminogen activator (rt-PA). Although the drug has a definite effect in improving the prognosis of neurological function, it usually exceeds the time window of medication because the patient usually arrives at the hospital after 3 hours of onset. Therefore, most ischemic stroke patients failed to receive rt-PA treatment. The current study suggests that the most likely way to increase the number of rt-PA treatments is to extend the treatment window. European Cooperative Acute Stroke Study (ECASS) -3 is a prospective study,